Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | MDM4 | O15151 | 4/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894030 | 0.87 | MDM2 (0.44) | CNR1CNR2MDM2 | |
| SCHEMBL1437062 | 0.85 | CNR1 (0.40) | CNR1CNR2 | |
| SCHEMBL9894160 | 0.83 | GABRA2 (0.46) | KDM4ENPC1RAB9AMDM2GABRA2 | |
| SCHEMBL9893870 | 0.80 | KDM4E (0.46) | KDM4ENPC1RAB9AGABRA2GABRB2 | |
| SCHEMBL1436909 | 0.79 | ALDH1A1 (0.43) | KDM4EMDM4MDM2GABRA2GABRB2 | |
| SCHEMBL9894075 | 0.77 | MDM2 (0.56) | KDM4ECNR2MDM4MDM2GABRA2 | |
| SCHEMBL9893965 | 0.76 | MDM2 (0.48) | CNR1CNR2MDM2GABRA2GABRB2 | |
| SCHEMBL1437067 | 0.76 | MDM2 (0.57) | KDM4EMDM4MDM2TP53ALDH1A1 | |
| SCHEMBL9894088 | 0.76 | PDE4B (0.41) | KDM4EMDM4MDM2TP53ALDH1A1 | |
| SCHEMBL1440068 | 0.76 | MDM2 (0.57) | MDM2GABRA2GABRB2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | KDM4E 983/4885NPC1 3324/4885RAB9A 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.